NEUROMODULATORS IN THE CONSERVATIVE TREATMENT OF TMD

Session

Dental Sciences

Description

Aim: The second most common orofacial pain in the population aged 20 - 45 years is the pain from TMD. Ethiopathology of the diseases is complex, but the symptomatology is similar and they are presented with symptoms originating in the joint and masticatory muscles. The aim of the study was to evaluate the effectiveness of neuromodulator botulinum toxin in TMD treatment for relieving chronic pain and muscle spasm.

Material and methods: As part of the conservative, conventional therapeutic protocol for the treatment of bruxism manifested by hyperactivity, hypertrophy and chronic pain in the masticatory muscles botulinum toxin type A (Dysport 300, Ipsen, UK) was administered bilaterally, in three points, a total of 40 units in each muscle in two consecutive sessions.

Results: After a period of 2 weeks required for the full action of the toxin, the patient recorded a significant reduction in pain and infrequent episodes of clenching and grinding of the teeth. Control examinations were performed after 1 and 3 months. Mild hypotrophy of the muscles with reduced gonial angle of the mandible change was observed bilaterally in both masseters.

Conclusion: Neuromodulator botulinum toxin can be successfully used in conventional therapy of muscle disorders due to minimal invasiveness, reversibility and minimal side effects.

Keywords:

temporomandibular dysfunction, botulinum toxin, myospasm

Proceedings Editor

Edmond Hajrizi

ISBN

978-9951-550-50-5

Location

UBT Kampus, Lipjan

Start Date

29-10-2022 12:00 AM

End Date

30-10-2022 12:00 AM

DOI

10.33107/ubt-ic.2022.230

This document is currently not available here.

Share

COinS
 
Oct 29th, 12:00 AM Oct 30th, 12:00 AM

NEUROMODULATORS IN THE CONSERVATIVE TREATMENT OF TMD

UBT Kampus, Lipjan

Aim: The second most common orofacial pain in the population aged 20 - 45 years is the pain from TMD. Ethiopathology of the diseases is complex, but the symptomatology is similar and they are presented with symptoms originating in the joint and masticatory muscles. The aim of the study was to evaluate the effectiveness of neuromodulator botulinum toxin in TMD treatment for relieving chronic pain and muscle spasm.

Material and methods: As part of the conservative, conventional therapeutic protocol for the treatment of bruxism manifested by hyperactivity, hypertrophy and chronic pain in the masticatory muscles botulinum toxin type A (Dysport 300, Ipsen, UK) was administered bilaterally, in three points, a total of 40 units in each muscle in two consecutive sessions.

Results: After a period of 2 weeks required for the full action of the toxin, the patient recorded a significant reduction in pain and infrequent episodes of clenching and grinding of the teeth. Control examinations were performed after 1 and 3 months. Mild hypotrophy of the muscles with reduced gonial angle of the mandible change was observed bilaterally in both masseters.

Conclusion: Neuromodulator botulinum toxin can be successfully used in conventional therapy of muscle disorders due to minimal invasiveness, reversibility and minimal side effects.